08.08.2023 | Published by bit.bio

A Molecular Portrait of ALS and FTD

Featured Image

On April 30th, 1939, baseball hall of famer Lou Gehrig stepped up to the plate with weary muscles. Over the course of Gehrig’s 15-year career, fans and teammates had dubbed him the “Ironhorse” as a nod to the fact that neither illness, injury, nor fatigue had ever caused him to miss a game. The man was, it seemed, invincible. But on this day, the Ironhorse’s 2130th consecutive game would also prove to be his last1,2.

Though he was only 37, the motor neurons in Gehrig’s body had begun to deteriorate, weakening his muscles, degrading his coordination, and robbing him of his famed athleticism. Unbeknownst to him, these symptoms were the signs of amyotrophic lateral sclerosis (ALS), a rapidly progressive and fatal neurodegenerative condition that many now know as Lou Gehrig’s disease. 

Gehrig’s declining health prevented him from playing another game, but his fame brought the world’s attention to this enigmatic disease and others like it.

In the sections that follow, we dive in on the latest research describing the underlying causes of ALS and a closely related condition known as frontotemporal dementia (FTD), two forms of neurodegenerative disease that share striking similarities in their molecular pathologies. We’ll also highlight the need for more robust, scalable, and consistent cell models of FTD and ALS.

What is amyotrophic lateral sclerosis (ALS)? 

ALS is the most common motor neuron disease and is estimated to affect more than 80,000 people worldwide3. All ALS patients share the same progressive dysfunction and death of motor neurons in either the primary motor cortex, the spinal cord, or both. This loss manifests as muscle paralysis and atrophy that can ultimately reduce a patient's ability to breathe. The average life expectancy following symptom onset is ~2-5 years4,5. And while patients share common molecular hallmarks, the wide heterogeneity among ALS subtypes suggests that it may not be a single disease, but rather a common outcome of multiple neurodegenerative processes6

To this end, ALS patients often show overlapping clinical representation to other neurodegenerative disorders, particularly frontotemporal dementia, with particular similarities to the underlying molecular mechanisms of disease.

What is frontotemporal dementia (FTD)?

FTD is a neurodegenerative disease characterised by the progressive death of Glutamatergic and GABAergic neurons in the frontal and temporal lobes, with some evidence pointing to decreases in neurotransmitters like GABA contributing to disease presentation7,8. The cumulative loss of these neurons and the disruption of neurotransmitter levels can have a range of debilitating effects that alter patient behaviour and cognition. Similar to ALS, there appear to be numerous molecular factors contributing to the onset of FTD, which has led experts to suggest that FTD is not a singular disorder, but rather a shared neurodegenerative outcome resulting from various mechanisms.

Modelling ALS and FTD without noise

Modelling neurodegenerative disease isn’t easy. Whether its differences between human and preclinical animal models, or the donor variability that comes with human cell models, inconsistencies in FTD and ALS models have greatly limited research progress. bit.bio has developed human iPSC-derived ALS and FTD models that solve the consistency problem and demonstrate disease-related phenotypes. With isogenic controls, consistency at scale, and fast turnaround times, these cells are already advancing the field. 

Learn about our ALS and FTD disease models >


Hallmarks of ALS and FTD

ALS and FTD are not always easy to distinguish, and disease symptoms show cross-over (Table 1). Roughly 50% of patients with ALS also develop cognitive or behavioural impairments, while 30% of FTD patients may also show motor neuron dysfunction9. This overlap is mirrored at a genetic level, where current research suggests that approximately 20% of genes linked to one disease are also linked to the other10. Given these similarities, many have begun to view these conditions as two points on a single neuropathological spectrum, with each driven by shared pathological processes11.

In this light, it’s not surprising that FTD and ALS present with many of the same molecular hallmarks, including atypical protein aggregates, lysosomal dysfunction, and axonal degeneration (among many others)7,10,11,12,13,14. Studying these hallmarks and their relationship to disease pathology may not only advance our understanding of FTD and ALS, but uncover broader insights about the molecular mechanisms driving the function and potential dysfunction of the human brain.

Table 1. Similarities in the hallmarks of FTD and ALS


Heterogenous disease, broadly characterised by progressive language, behavioural and executive deficits15

Progressive disease with heterogenous symptoms, many patients present with decreased motor function, muscle atrophy, and some developing cognitive dysfunction as well13

Familial vs. sporadic

~30-50% of patients report family history of FTD15

~85-90% cases are classified as sporadic, with no family history of ALS13

Primary affected cells

Pyramidal cortical neurons in the frontal and temporal lobes7

Motor neurons in the brain and spinal cord4


Up to 30% of patients also develop motor defects associated with ALS9

Up to 50% of patients also develop symptoms associated with FTD9


Protein aggregates

Examination of neurons from both FTD and ALS patients reveals the existence of atypical protein aggregates in the cells’ cytoplasm. The specific proteins found in these aggregates can vary, but approximately 95% of ALS patients and 50% of FTD patients develop aggregates containing the TDP-43 protein (short for tar DNA binding protein 43)14

TDP-43 is a DNA and RNA binding protein that regulates the expression and splicing of several target transcripts16. In healthy patients, nuclear expression of TDP-43 is ubiquitous throughout neurons in the central nervous system. In contrast, patients with ALS and FTD show a redistribution of TDP-43 in affected nerve cells, sometimes accompanied by a decrease in nuclear expression17,18,19. Abnormal TDP-43 distribution coincides with increased TDP-43 phosphorylation as well as TDP-43 aggregation in the neuronal cytoplasm and axon. The cause of TDP-43 mislocalisation is unclear20,21.

Precisely how TDP-43 aggregates mediate neuronal toxicity is also not yet clear. There are several possibilities, but two main mechanisms highlighted in current research include toxicity stemming from the aggregates themselves, from a loss of TDP-43 nuclear activity, or a combination of the two among many other possibilities. Many potential toxic effects have been suggested, including the mis-splicing of the Stathmin-2 RNA transcript14.

Degenerating neuronsFigure 1. Image modified from Suk et al. [reference 21]. Mislocalization of TDP-43 (red) causes various effects on neurons, ranging from disrupted RNA splicing to dysregulation of lysosomes and autophagic machinery. These effects promote neuron cell death and exacerbate ALS and FTD disease pathology. Targeting TDP-43 mislocalization is one of many potential therapeutic approaches.

Stathmin-2 is one of many proteins that appear critical for the growth and stabilisation of axons, most likely by regulating the dynamics of axonal microtubules22. Under normal conditions, TDP-43 prevents cells from using a cryptic splice site on the Stathmin-2 transcript. In ALS and FTD, however, when TDP-43 is sequestered in the cytoplasm, this cryptic splice site is de-repressed, enabling cells to access a cryptic poly-A site (normally hidden in an intron). Consequently, use of the site produces a transcript containing a premature poly-A tail that truncates the final protein. This truncated form of Stathmin-2 is unable to properly regulate microtubule dynamics, ultimately degrading axonal integrity22.

Axonal degeneration

Both ALS and FTD present with the pathological degradation of axons preceding cell death. Axons are supported by an underlying framework of protein filaments known as microtubules. The regulated growth and destruction of microtubules are essential to the growth of axons and their associated neurites. Additionally, microtubules serve as molecular highways along which proteins and other cargo can be ferried from the cell body to distal axonal locations23.

Destruction of the microtubule filaments can be catastrophic for neurons, leading to abnormal electrophysiology and eventual degeneration of the axon. Not surprisingly, diseases like FTD and ALS often feature abnormal regulation of microtubule associated proteins (MAPs) that influence microtubule dynamics24, 25

Tau is another MAP that is frequently associated with FTD and can be found in atypical aggregates. One of the most well-studied MAPs, Tau is known to bind to growing microtubules where it helps to prevent the filament from unfurling26. However, hyperphosphorylation of Tau can decrease its affinity for the microtubules and, in turn, the stability of axons. 

Approximately 50% of FTD patients show abnormal regulation of Tau, whether it's through hyperphosphorylation or a change in the ratio of Tau isoforms that can lead to Tau aggregation14. Either way, the end result is the same: microtubule stability goes down, and with it, axonal degeneration proceeds. 

Lysosomal disorder

Recent studies suggest that FTD and ALS may be driven by disordered regulation and function of lysosomes12. By sequestering and degrading cellular material, lysosomes play an invaluable role in maintaining cellular homeostasis. Loss of this function can result in a pathological buildup of proteins and other substances that have a particularly pronounced effect on the central nervous system. Not surprisingly, lysosomal storage disorders often show CNS pathologies. 

Several lines of evidence suggest the presence of lysosomal dysfunction in FTD and ALS. Tissues collected from affected patients, for example, show lipofuscin deposits, glycosphingolipids, and reduced nuclear localisation of transcription factor EB (TFEB)—a master transcriptional regulator of lysosomal genes. Additionally, many of the proteins associated with ALS and FTD, such as Tau and TDP-43, have been shown to disrupt lysosomal dynamics12.

Insights like these strongly suggest that whatever the trigger, lysosomal dysfunction can help fuel a catastrophic cascade that promotes protein aggregate formation, axonal collapse, and eventual cell death.

Towards understanding the neuropathological spectrum

Each of the hallmarks mentioned in Table 2 is common in FTD and ALS patients, but they are not unique to these diseases. The hallmarks are also variably observed in other neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease13. Therefore studying the relationship between protein aggregation, lysosomal dysfunction, and axonal degeneration can have implications well beyond FTD and ALS. 

Table 2. Similarities in the cytology and molecular characteristics of ALS and FTD

Protein aggregates

~50% of patients with abnormal protein aggregates show TDP-43 inclusions; ~50% present with Tau protein aggregates14

95% of patients show cytoplasmic protein aggregates of TDP-4326

Familial vs. sporadic neuronal pathology

Neuronal pathology includes abnormal protein aggregations in cytoplasm and axons, excitotoxicity, abnormal electrophysiology, axonal degeneration, and eventual cell death7

Neuronal pathology includes abnormal protein aggregations in cytoplasm and axons, excitotoxicity, abnormal electrophysiology, axonal degeneration, and eventual cell death7

Microtubule dysregulation

Dysregulation of Stathmin-2 and Tau, depending on molecular subtype13,14

Dysregulation of microtubule associated protein Stathmin-214

Lysosomal dysfunction

Strongly implicated. Histological biomarkers observed in FTD and lysosomal storage disease patients. Mutations associated with FTD known to affect proteins that interact with lysosomes12

Strongly implicated. Post-mortem brain tissue shows 62% reduction in key transcription factor controlling expression of lysosomal genes. Mutations associated with ALS known to affect proteins that interact with lysosomes12

Common mutations
  • Microtubule Associated Protein Tau (MAPT)
  • Progranulin (GRN)
  • Chromosome 9 open reading frame 72 (C9ORF72)7
  • Superoxide dismutase 1 (SOD1)
  • Chromosome 9 open reading frame 72 (C9ORF72)
  • Transactive response DNA-binding protein 43 (TARDBP)
  • Fused in sarcoma (FUS)7, 27


Current research suggests that these shared hallmarks have a causal relationship with one another, but the precise interplay between them is still being worked out. For example, TDP-43 mislocalisation may alter the expression of key genes that regulate microtubule stability, but it may also influence lysosomal dynamics, autophagy, and mitochondrial function among many other processes. Whether TDP-43 mislocalisation precedes lysosomal dysfunction and disease development, or vice versa, remains to be seen.

Researchers need accurate model systems that allow for the meticulous study of these molecular hallmarks to better understand (and hopefully treat) ALS, FTD, and other neurodegenerative diseases. While such a task has historically been difficult, new opportunities are opening up with the advancement of precision cellular reprogramming technology.

bit.bio has recently developed human iPSC-derived neurons that harbour a key mutation in the TARDBP gene encoding the TDP-43 protein and human iPSC-derived neurons with two different mutations in the MAPT gene encoding Tau. Preliminary data suggests that these cells show key hallmarks of FTD and ALS. This data can be explored further in our scientific poster presented at AD/PD 2023. In providing a consistent and scalable model of neurodegenerative disease, these neurons open the door to more accurate, large-scale, and high-throughput research into neurodegenerative processes and therapeutic development. To learn more about the use of ioCells™ in FTD and ALS research, watch our recent webinar: Precision Cellular Reprogramming for Scalable and Consistent Human Neurodegenerative Disease Models.


  1. “Gehrig Is Second on MLB’s Consecutive Games List.” MLB.com, www.mlb.com/news/most-consecutive-games-played-in-mlb-history-c282212708. Accessed 5 May 2023.
  2. April 30, 1939: Lou Gehrig Plays His Final Game with Yankees – Society for American Baseball Research. sabr.org/gamesproj/game/april-30-1939-lou-gehrig-plays-his-final-game-with-yankees/. Accessed 5 May 2023.
  3. Arthur, Karissa C., et al. “Projected Increase in Amyotrophic Lateral Sclerosis from 2015 to 2040.” Nature Communications, vol. 7, no. 1, 11 Aug. 2016, www.ncbi.nlm.nih.gov/pmc/articles/PMC4987527/, https://doi.org/10.1038/ncomms12408.
  4. Zarei, S., et al. “A comprehensive review of amyotrophic lateral sclerosis”. Surg Neurol Int. vol 16;6:171, Nov 2015, https://doi.org/10.4103/2152-7806.169561.
  5. Marin, B., et al. “Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin”. Eur J Epidemiol vol. 31, 2016, pp. 229–245, https://doi.org/10.1007/s10654-015-0090-x
  6. “Frontotemporal Dementia vs. ALS.” ALS Therapy Development Institute, www.als.net/news/frontotemporal-dementia-vs-als/. Accessed 5 May 2023.
  7. Guo, Wenting, et al. “Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells.” Frontiers in Neuroscience, vol. 11, 13 Dec. 2017, https://doi.org/10.3389/fnins.2017.00671.
  8. Huber, N., et al. “Deficient neurotransmitter systems and synaptic function in frontotemporal lobar degeneration-Insights into disease mechanisms and current therapeutic approaches”. Mol Psychiatry vol. 27, no. 3, Mar. 2022, pp.1300-1309. doi: https://doi.org/10.1038/s41380-021-01384-8
  9. Abramzon, Yevgeniya A., et al. “The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.” Frontiers in Neuroscience, vol. 14, 5 Feb. 2020, https://doi.org/10.3389/fnins.2020.00042.
  10. Liscic, Rajka Maria, et al. “From Basic Research to the Clinic: Innovative Therapies for ALS and FTD in the Pipeline.” Molecular Neurodegeneration, vol. 15, no. 1, 1 June 2020, https://doi.org/10.1186/s13024-020-00373-9.
  11. Ling, Shuo-Chien et al. “Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.” Neuron vol. 79,3 (2013): 416-38. doi:10.1016/j.neuron.2013.07.033
  12. Root, Jessica, et al. “Lysosome Dysfunction as a Cause of Neurodegenerative Diseases: Lessons from Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.” Neurobiology of Disease, vol. 154, July 2021, p. 105360, https://doi.org/10.1016/j.nbd.2021.105360.
  13. Virgilio, E., et al. “The Role of Tau beyond Alzheimer's Disease: A Narrative Review.” Biomedicines vol. 10 no. 4, 24 Mar. 2022, https://doi.org/10.3390/biomedicines10040760.
  14. Glass, Jonathan D. “Stathmin-2: Adding Another Piece to the Puzzle of TDP-43 Proteinopathies and Neurodegeneration.” Journal of Clinical Investigation, vol. 130, no. 11, 19 Oct. 2020, pp. 5677–5680, https://doi.org/10.1172/jci142854
  15. Woollacott, Ione O. C., and Jonathan D. Rohrer. “The Clinical Spectrum of Sporadic and Familial Forms of Frontotemporal Dementia.” Journal of Neurochemistry, vol. 138, 15 June 2016, pp. 6–31, https://doi.org/10.1111/jnc.13654.
  16. Lee, Sebum, and Eric J. Huang. “Modeling ALS and FTD with IPSC-Derived Neurons.” Brain Research, vol. 1656, Feb. 2017, pp. 88–97, https://doi.org/10.1016/j.brainres.2015.10.003.
  17. Riva, N., et al. “Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis”. Brain vol. 145, no. 1, Mar. 29 2022, pp. 276-284. https://doi.org/10.1093/brain/awab285
  18. Giordana, M. T., et al. “TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis”. Brain Pathol vol. 20, no. 2, Mar. 2010, pp. 351-60. doi:  https://doi.org/10.1111/j.1750-3639.2009.00284.x
  19. Neumann, M., et al. “Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.” Science vol. 314. https://doi.org/10.1126/science.1134108
  20. Corcia, P., et al. “Phenotype and Genotype Analysis in Amyotrophic Lateral Sclerosis with TARDBP Gene Mutations.” Neurology, vol. 78, no. 19, 25 Apr. 2012, pp. 1519–1526, https://doi.org/10.1212/wnl.0b013e3182553c88
  21. Suk, T.R., Rousseaux, M.W.C. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegeneration 15, 45 (2020). https://doi.org/10.1186/s13024-020-00397-1
  22. Melamed, Ze’ev, et al. “Premature Polyadenylation-Mediated Loss of Stathmin-2 Is a Hallmark of TDP-43-Dependent Neurodegeneration.” Nature Neuroscience, vol. 22, no. 2, 1 Feb. 2019, pp. 180–190, https://doi.org/10.1038/s41593-018-0293-z.
  23. Baas, Peter W., et al. “Stability Properties of Neuronal Microtubules.” Cytoskeleton, vol. 73, no. 9, Sept. 2016, pp. 442–460, https://doi.org/10.1002/cm.21286.
  24. Yang, Xiaoman, et al. “Common mechanisms underlying axonal transport deficits in neurodegenerative diseases: a mini review.” Front. Mol. Neurosci. vol 16, 24 April 2023, https://doi.org/10.3389/fnmol.2023.1172197
  25. Bodakuntla, Satish, et al. “Microtubule-Associated Proteins: Structuring the Cytoskeleton.” Trends Cell Bio. vol. 29, no. 10, Oct. 2019, pp. 804-819, https://doi.org/10.1016/j.tcb.2019.07.004
  26. Barbier, Pascale, et al. “Role of Tau as a Microtubule-Associated Protein: Structural and Functional Aspects.” Front. Aging Neurosci., vol. 11, 7 Aug. 2019, https://doi.org/10.3389/fnagi.2019.00204
  27. Liguori, Francesco, et al. “Where and Why Modeling Amyotrophic Lateral Sclerosis.” International Journal of Molecular Sciences, vol. 22, no. 8, 12 Apr. 2021, p. 3977, https://doi.org/10.3390/ijms22083977

Related pages

About us Coding cells to advance the wellbeing of humanity
Careers See the latest openings
News See the latest news